Why Is ARTV Stock Skyrocketing Today? FDA Fast Track Sends Shares Up Over 100%

Artiva Biotherapeutics (NASDAQ:ARTV) stock exploded on Friday, October 17, 2025, surging over 93% following a major regulatory milestone. The clinical-stage biotechnology company announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its AlloNK cell therapy candidate in combination with rituximab for treating refractory rheumatoid arthritis. This marks AlloNK as the first deep B-cell depleting therapy to receive this designation for refractory RA, a condition affecting more than 100,000 U.S. patients who have not responded to all approved therapies.

The stock opened at $5.59 after closing at $2.77 the previous day, with trading volume exceeding 52 million shares compared to the three-month daily average of approximately 408,000 shares.

FDA’s Decision Signals Confidence in AlloNK’s Clinical Potential

The FDA’s Fast Track Designation represents a significant validation of Artiva’s approach to addressing refractory rheumatoid arthritis, a challenging condition where patients no longer respond to conventional treatments including methotrexate, TNF inhibitors, and B-cell depleting antibody monotherapy. Artiva’s unmodified, off-the-shelf AlloNK cells are designed to enhance B-cell depleting antibodies through antibody-dependent cellular cytotoxicity, potentially driving deeper and more durable patient responses. The company has prioritized refractory RA as its lead autoimmune indication for the AlloNK clinical development program.

CEO Fred Aslan emphasized the significance of this underserved patient population, noting that despite many approved RA therapies, over 100,000 U.S. patients remain treatment refractory and could potentially benefit from a deep B-cell depleting therapy. The company plans to share patient safety data in November 2025, followed by clinical response data from more than 15 refractory RA patients in the first half of 2026. Artiva also expects to conduct regulatory interactions with the FDA during that same timeframe, setting the stage for potential advancement of the therapy.

H.C. Wainwright reiterated a Buy rating on Artiva stock with a $12.00 price target following the announcement, highlighting the significant unmet medical need. The analyst community shows strong support for the company, with a consensus Strong Buy rating based on five Buy ratings over the past three months and an average price target of $14.50, suggesting potential upside of over 400% from pre-announcement levels.

Join our Telegram group and never miss a breaking digital asset story.

Massive Volume and Analyst Upgrades Fuel Investor Optimism

As of 10:59 AM EDT on October 17, 2025, ARTV stock was trading at $5.36, up $2.59 or 93.65% from the previous close of $2.77. The stock opened at $5.59 and traded in a range of $5.14 to $6.19 during the session. This dramatic surge follows a challenging period for the stock, which had fallen 72.52% year-to-date and 77.24% over the past 12 months, with a 52-week range of $1.47 to $15.49. The market capitalization stood at approximately $132 million following the rally.

The trading activity was extraordinary, with over 52.5 million shares changing hands, representing more than 100 times the average daily volume of approximately 408,000 shares. According to financial data, Artiva maintains a strong liquidity position with a current ratio of 13.84 and more cash than debt on its balance sheet, holding $142.36 million in total cash as of the most recent quarter. However, the company is currently burning through cash rapidly and reported negative earnings per share of $6.15 over the trailing twelve months.

Despite the company’s pre-revenue status and current cash burn, the Fast Track Designation has reinvigorated investor confidence in Artiva’s development strategy. Wedbush, in the latest analyst rating on October 17, 2025, maintained an Outperform rating and raised its price target from $18 to $23, reflecting increased optimism about the commercial potential of AlloNK in the refractory RA indication and potentially other autoimmune and oncology applications.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.